Company Overview

Octapharma, a Swiss-based company, is an independent, global plasma fractionation specialist. Its core business is the development, production and sale of high quality plasma derivatives.
- From its foundation in 1983 the company has grown to employ over 1300 people in 25 countries. Octapharma owns four modern, state-of-the-art production facilities in Austria, France, Sweden and Mexico. Sales turnover in 2004 exceeded Euro 345 million.
- Octapharma continues to grow and invest heavily in the future. Profits, are mainly channelled into R&D and further improvements and expansion of Production.
- In the highly demanding market of life-saving plasma products, company success is only possible through reliable product quality and a proven safety record.

Octapharma Mission

Since the foundation of Octapharma in 1983 the company has had a clear and consistent mission:

 'For the safe and optimal use of plasma'

Octapharma respects donated human plasma as a scarce and valuable resource. By using leading edge, validated viral inactivation and purification technologies Octapharma aims to achieve the highest production yields and produce products with the highest possible safety margins.

Product Overview

The Octapharma product portfolio is focused on plasma derivates and includes all major plasma proteins, such as immunoglobulins, coagulation factors VIII or IX and albumin. It also includes a standardised, SD virus-inactivated plasma for transfusion.